Obesity and other lifestyle-related diseases are, amongst others, the result of an unbalanced diet and lifestyle. Excessive intake of energy, salt, saturated fat and sugar are leading to increased risk of chronic diseases, such as cardiovascular diseases, cancer and diabetes (WHO/FAO). Therefore, a healthier food intake (diet) is needed. But when is a food product healthier? From a nutritional perspective it is clear: the lower the levels of nutrients with a negative public health impact, the better the product fits in a healthy diet. However, when it comes to improving the health impact of the food supply through reformulation, other aspects are important as well. This article describes the ‘framework for product reformulation’, which integrates four essential disciplines: Nutrition & health, Foodtechnology, Legislation and Consumer perspective.
MULTIFILE
Five methods were compared to determine the best technique for accurate identification of coagulase-negative staphylococci (CoNS) (n=142 strains). MALDI-TOF MS showed the best results for rapid and accurate CoNS differentiation (correct identity in 99.3%). An alternative to this approach could be Vitek2 combined with partial tuf gene sequencing.
Conducted for the 2019 Venice Bienale catalogue of the Romanian pavillion, in particular Canal Grande: The Capital Pool and the Associated Public of Dan Mihaltianu, curated by Cristian Nae. The work “functions at first sight as a wishing well. It establishes an autonomous art fund and invites the visitors to self-organize and to decide on the utilization of the capital raised during the exhibition via capitalpool.net, proposing an artistic formula for exercising direct democracy.”
MULTIFILE
The global market for the industrial manufacturing of recombinant proteins (RPS) is steadily increasing and demand will keep rising in years to come. Currently, RPs are already an integral part of disease therapeutics, agriculture and the chemical industry and RP manufacturing methods rely heavily on host systems such as prokaryotes and, to a lesser extent, mammalian, yeast and plant cells. When comparing these host systems, all have their specific strengths and weaknesses and numerous challenges remain to improve protein manufacturing on an industrial scale. In this project, GLO Biotics proposes an innovative plant-based RP expression platform with the potential of significantly reducing costs and process requirements compared to the current state-of-the-art systems. Specifically, this novel concept is based on the use of coconut water as a natural, cell-free ‘protein production factory’. Coconut water in nuts aged 4-6 months is composed of free-floating cell nuclei devoid of cell walls, and it has been demonstrated these nuclei can express foreign proteins. Compared to existing platforms, the relative ease of delivering foreign protein-coding genes into this system, as well as the ease of recovery of the produced protein, potentially offers an innovative platform with great commercial attractiveness. In summary, the aim of this project is to provide a proof-of-concept for coconut water as a novel and competitive RP production platform by demonstrating the production and recovery of several commercially available RPs. To this end, GLO Biotics intends to collaborate with Zuyd University of Applied Sciences (Zuyd) and the Aachen Maastricht Institute for Biobased Materials (AMIBM) in demonstrating the potential of the ‘GLO-Conuts’ expression system. As a consortium, Zuyd and GLO Biotics will utilize their shared experience in molecular engineering and DNA vector technology and AMIBM will bring their expertise in plant-based RP production and recovery.
The missing link in diagnostic testing for rheumatoid arthritis (RA) is an agglutination assay, easy to perform and dedicated to decentralized testing. Approximately 75% of RA patients produce autoantibodies to citrullinated proteins (ACPA), which can be detected using an agglutination-based diagnostic test. Such a diagnostic test will be cheaper, less laborious and faster than current tests and does not require sophisticated equipment. Novio Catalpa is developing this alternative test for ACPA in collaboration with Radboud University. To develop this test, specifically tagged and citrullinated nanobodies are needed, but the production is still challenging. Current methods for the production of ACPA diagnostics involve chemical synthesis, in which a variety of toxic chemicals are used in each step. The alternative assay involves nanobodies fused with RA-biomarker target entities, which can be completely produced by ‘green synthesis’ in the yeast Pichia pastoris using the expertise of HAN BioCentre. The yeast P. pastoris has proven to be able to produce nanobodies and is a fast and cost-effective platform that often results in high protein yields. Goal of the project is therefore to determine the feasibility and best green route to produce purified nanobodies tagged with citrullinated ACPA targets that can be used for developing an agglutination assay for RA. P. pastoris does not produce endogenous PAD enzymes which are needed for citrullination of the nanobodies in order to be able to use it in a RA agglutination test. Therefore, PAD enzymes from other sources need to be tested and applied. The project results will be directly used by Novio Catalpa to further develop the innovative test for RA. This project will contribute to and finally result in a single-step agglutination assay suitable for both point-of-care testing and automation in clinical laboratories.
Green methanol is emerging as a key player in sustainable biotech, offering a renewable alternative to fossil fuels or sugar based feedstocks. Although methanol has long been considered a promising material for bioproduction, using it on industrial scale has been challenging due to its high oxygen demands, making the process expensive and inefficient. This project focuses on developing a sustainable, but more economical feasible way to produce biochemicals, like Single Cell Protein (SCP). The innovative solution proposed by FeedstocksUnited (FSU) is to use paraformaldehyde, a compound derived from renewable methanol, as feedstock, which requires much less oxygen during fermentation. This new method has already shown promising results in the lab, where it was tested with microorganisms that can use formaldehyde (released from paraformaldehyde) as a source of carbon and energy. FSU’s approach has the potential to significantly reduce the costs and environmental impacts associated with large-scale bioproduction. The process can be managed more efficiently than methods using methanol, since the production of paraformaldehyde from formaldehyde is tunable. This process control will lead to better yields and reduced energy and feedstock consumption. The HAN BioCentre, with its advanced research facilities and experienced team, will conduct further research to optimize this method for industrial applications. This includes studying how organisms metabolize formaldehyde and improving the process through continuous fermentation. The research also supports educational goals by involving students in cutting-edge biotechnological work. Ultimately, the project aims to provide a solid proof-of-concept that can be scaled up to industrial levels, contributing to a more sustainable bioeconomy.
